Boundless Bio

Q2 FY2026 EarningsQ2 FY26 missed consensus across all key profitability and cash flow metrics as the company prepares for a strategic merger with Serapha Bio. Net loss of -$23.7M was significantly wider than the -$13.1M consensus, driven by massive one-time lease termination and workforce reduction charges. EPS GAAP of -$1.06 missed the -$0.58 estimate, and cash from operations for the first half was -$35.9M vs. the -$15.2M expected for the quarter, reflecting a total wind-down of legacy oncology programs and a transition toward the merger's closure in Q4 2026.